Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.

Rhee SY, Clutter D, Fessel WJ, Klein D, Slome S, Pinsky BA, Marcus JL, Hurley L, Silverberg MJ, Kosakovsky Pond SL, Shafer RW.

Clin Infect Dis. 2019 Jan 7;68(2):213-221. doi: 10.1093/cid/ciy453.

2.

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.

Manasa J, Varghese V, Pond SLK, Rhee SY, Tzou PL, Fessel WJ, Jang KS, White E, Rögnvaldsson T, Katzenstein DA, Shafer RW.

Sci Rep. 2017 Sep 14;7(1):11559. doi: 10.1038/s41598-017-11893-8.

3.

Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment.

Fessel WJ.

Am J Alzheimers Dis Other Demen. 2017 May;32(3):166-181. doi: 10.1177/1533317517698790. Epub 2017 Mar 17. Review.

PMID:
28423937
4.

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.

Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P.

Hepatol Int. 2017 Mar;11(2):188-198. doi: 10.1007/s12072-017-9788-z. Epub 2017 Feb 16.

PMID:
28210927
5.

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.

Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A, Subramanian GM, McHutchison JG, Ferrari C, Lee H, Gordon SC, Gane EJ.

J Hepatol. 2016 Sep;65(3):509-16. doi: 10.1016/j.jhep.2016.05.016. Epub 2016 May 19.

PMID:
27210427
6.

Response to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug Resistance.

Clutter DS, Fessel WJ, Rhee SY, Hurley LB, Klein DB, Ioannidis JP, Silverberg MJ, Shafer RW.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):171-6. doi: 10.1097/QAI.0000000000000942.

7.

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; PHOTON-1 Investigators.

JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734. Erratum in: JAMA. 2014 Nov 12;312(18):1932.

8.

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J, Towner W, Troia P, Burack J, Dejesus E, Robbins GK, Razzeca K, Kagan R, Liu TF, Fessel WJ, Israelski D, Shafer RW.

J Antimicrob Chemother. 2014 Jan;69(1):12-20. doi: 10.1093/jac/dkt316. Epub 2013 Aug 9.

9.

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1.

Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW.

Antimicrob Agents Chemother. 2013 Sep;57(9):4290-4299. doi: 10.1128/AAC.00614-13. Epub 2013 Jun 24.

10.

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance.

Babrzadeh F, Varghese V, Pacold M, Liu TF, Nyrén P, Schiffer C, Fessel WJ, Shafer RW.

J Antimicrob Chemother. 2013 Feb;68(2):414-8. doi: 10.1093/jac/dks409. Epub 2012 Oct 19.

11.

Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.

Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.

12.

Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes.

Rhee SY, Blanco JL, Liu TF, Pere I, Kaiser R, Zazzi M, Incardona F, Towner W, Gatell JM, De Luca A, Fessel WJ, Shafer RW.

AIDS Res Ther. 2012 May 3;9(1):13. doi: 10.1186/1742-6405-9-13.

13.

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.

Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia-Cancio PV, Zolopa A, Robbins GK, Kagan R, Israelski D, Shafer RW.

Antimicrob Agents Chemother. 2012 May;56(5):2305-13. doi: 10.1128/AAC.05487-11. Epub 2012 Feb 13.

14.

Association of osteonecrosis and peripheral neuropathy in HIV-1-infected patients: possible roles of nerve growth factor and vascular endothelial growth factor.

Fessel WJ, Chau Q, Leong D.

AIDS. 2011 Nov 28;25(18):2305-6. doi: 10.1097/QAD.0b013e32834cdadd. No abstract available.

PMID:
22067199
15.

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.

Fessel WJ, Anderson B, Follansbee SE, Winters MA, Lewis ST, Weinheimer SP, Petropoulos CJ, Shafer RW.

Antiviral Res. 2011 Dec;92(3):484-7. doi: 10.1016/j.antiviral.2011.09.010. Epub 2011 Oct 4.

16.

Association of osteonecrosis and osteoporosis in HIV-1-infected patients.

Fessel WJ, Chau Q, Leong D.

AIDS. 2011 Sep 24;25(15):1877-80. doi: 10.1097/QAD.0b013e32834af637.

PMID:
21785318
17.

HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.

Varghese V, Liu TF, Rhee SY, Libiran P, Trevino C, Fessel WJ, Shafer RW.

AIDS Res Hum Retroviruses. 2010 Dec;26(12):1323-6. doi: 10.1089/aid.2010.0123. Epub 2010 Oct 21.

18.

HIV-1 protease mutations and protease inhibitor cross-resistance.

Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW.

Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.

19.

Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.

Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, Liu T, Mappala SJ, Gharizadeh B, Fessel WJ, Katzenstein D, Kassaye S, Shafer RW.

PLoS One. 2010 Jun 7;5(6):e10992. doi: 10.1371/journal.pone.0010992.

20.

Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.

Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW.

Antimicrob Agents Chemother. 2010 Feb;54(2):934-6. doi: 10.1128/AAC.01345-09. Epub 2009 Nov 16.

21.

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.

Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake LA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):309-15. doi: 10.1097/QAI.0b013e3181bca669.

22.

Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.

Shahriar R, Rhee SY, Liu TF, Fessel WJ, Scarsella A, Towner W, Holmes SP, Zolopa AR, Shafer RW.

Antimicrob Agents Chemother. 2009 Nov;53(11):4869-78. doi: 10.1128/AAC.00592-09. Epub 2009 Aug 31.

23.

Impaired neurocognition in HIV-infected patients: antecedents and treatment.

Fessel WJ.

AIDS. 2009 Aug 24;23(13):1731-3. doi: 10.1097/QAD.0b013e32832f061e. No abstract available.

PMID:
19574882
24.

Predictive value of HIV-1 genotypic resistance test interpretation algorithms.

Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW.

J Infect Dis. 2009 Aug 1;200(3):453-63. doi: 10.1086/600073.

25.

Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype.

Altmann A, Sing T, Vermeiren H, Winters B, Van Craenenbroeck E, Van der Borght K, Rhee SY, Shafer RW, Schülter E, Kaiser R, Peres Y, Sönnerborg A, Fessel WJ, Incardona F, Zazzi M, Bacheler L, Van Vlijmen H, Lengauer T.

Antivir Ther. 2009;14(2):273-83.

PMID:
19430102
26.

Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database.

Altmann A, Däumer M, Beerenwinkel N, Peres Y, Schülter E, Büch J, Rhee SY, Sönnerborg A, Fessel WJ, Shafer RW, Zazzi M, Kaiser R, Lengauer T.

J Infect Dis. 2009 Apr 1;199(7):999-1006. doi: 10.1086/597305.

PMID:
19239365
27.

Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.

Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.

Antimicrob Agents Chemother. 2009 May;53(5):2196-8. doi: 10.1128/AAC.01593-08. Epub 2009 Feb 17.

28.

Biomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infection.

Bembom O, Petersen ML, Rhee SY, Fessel WJ, Sinisi SE, Shafer RW, van der Laan MJ.

Stat Med. 2009 Jan 15;28(1):152-72. doi: 10.1002/sim.3414.

29.

Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.

Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, Shafer RW.

J Virol. 2008 Nov;82(21):10747-55. doi: 10.1128/JVI.01827-07. Epub 2008 Aug 20.

30.

Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.

Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW.

J Infect Dis. 2007 Oct 15;196(8):1177-9. Epub 2007 Sep 10.

31.

Virologic efficacy of boosted double versus boosted single protease inhibitor therapy.

Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, Fessel WJ.

AIDS. 2007 Jul 31;21(12):1547-54.

32.

Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance.

Altmann A, Beerenwinkel N, Sing T, Savenkov I, Doumer M, Kaiser R, Rhee SY, Fessel WJ, Shafer RW, Lengauer T.

Antivir Ther. 2007;12(2):169-78.

PMID:
17503659
34.

N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.

Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW.

AIDS Res Hum Retroviruses. 2006 Dec;22(12):1300-5.

35.

HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL.

Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Slome S, Flamm J, Horberg M, Hurley L, Klein D, Shafer RW.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):56-9.

36.

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, McGovern R, Adler E, McLaren C; BMS AI424-043 Study Group.

Curr Med Res Opin. 2005 Oct;21(10):1683-92.

PMID:
16238909
37.

HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.

Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW.

J Infect Dis. 2005 Aug 1;192(3):456-65. Epub 2005 Jul 5.

38.

Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy.

Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, Nguyen DP, Katzenstein D, Fessel WJ.

AIDS. 2004 Jul 23;18(11):1503-11.

39.

Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW.

J Virol. 2003 Apr;77(8):4836-47.

40.

Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.

Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, Shafer RW.

AIDS. 2003 Apr 11;17(6):791-9.

43.

Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.

Kantor R, Fessel WJ, Zolopa AR, Israelski D, Shulman N, Montoya JG, Harbour M, Schapiro JM, Shafer RW.

Antimicrob Agents Chemother. 2002 Apr;46(4):1086-92.

44.

Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial.

Haas DW, Fessel WJ, Delapenha RA, Kessler H, Seekins D, Kaplan M, Ruiz NM, Ploughman LM, Labriola DF, Manion DJ.

J Infect Dis. 2001 Feb 1;183(3):392-400. Epub 2000 Dec 29.

PMID:
11133370
45.

Thalidomide for the treatment of AIDS-associated wasting.

Kaplan G, Thomas S, Fierer DS, Mulligan K, Haslett PA, Fessel WJ, Smith LG, Kook KA, Stirling D, Schambelan M.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1345-55.

PMID:
11018854
46.

Salvage therapy and formulation of highly active antiretroviral therapy.

Fessel WJ, Follansbee SE, Young TP.

J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):194-5. No abstract available.

PMID:
10935698
47.

Dissociation of immunologic and virologic responses to highly active antiretroviral therapy.

Fessel WJ, Krowka JF, Sheppard HW, Gesner M, Tongson S, Weinstein S, Ascher M, Kwok S, Christopherson C.

J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):314-20.

PMID:
10836753
48.

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.

Saag MS, Fessel WJ, Kaufman CA, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarnieri JA, Lee J, Brenner-Gati L, Klausner M.

AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1413-7.

PMID:
10555103
49.

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, Fessel WJ, Moskovitz BL, Wiesinger B, Cosmatos D, Riser L, Thomas C, Hafner R, Dismukes WE.

Clin Infect Dis. 1999 Feb;28(2):291-6.

PMID:
10064246
50.

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

Oldfield EC 3rd, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, Chung R, Wagner KF, Paparello SF, Craig DB, Melcher G, Zajdowicz M, Williams RF, Kelly JW, Zelasky M, Heifets LB, Berman JD.

Clin Infect Dis. 1998 Mar;26(3):611-9.

PMID:
9524832

Supplemental Content

Loading ...
Support Center